Pegfilgrastim

證據等級: L5

預測適應症: 2 個

Pegfilgrastim: From [Original Indication Unavailable] to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Pegfilgrastim (DrugBank ID: DB00019) is a PEGylated long-acting G-CSF analog; original indication data is currently unavailable in this evidence pack. The TxGNN model predicts it may be effective for Severe Nonproliferative Diabetic Retinopathy, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only inference with no empirical evidence.

Quick Overview

Item	Content
Original Indication	Not available (no license data in Taiwan/US regulatory records)
Predicted New Indication	Severe Nonproliferative Diabetic Retinopathy
TxGNN Prediction Score	99.89%
Evidence Level	L5
US Market Status	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in structured form, but based on known pharmacology, pegfilgrastim is a PEGylated long-acting analog of G-CSF (granulocyte colony-stimulating factor). Its established mechanism is stimulating proliferation and differentiation of granulocyte precursor cells in bone marrow, and promoting mobilization of bone marrow stem cells/endothelial progenitor cells (EPCs) into circulation.

The theoretical link to diabetic retinopathy is indirect: EPC mobilization is sometimes associated with vascular repair pathways, which the TxGNN knowledge graph appears to have picked up as a similarity signal. However, this connection runs in a potentially concerning direction rather than a therapeutic one — G-CSF’s pro-angiogenic properties could theoretically worsen pathological neovascularization in proliferative or severe nonproliferative diabetic retinopathy, rather than treat it. There is no clinical or preclinical evidence supporting a therapeutic hypothesis in this direction; the mechanistic rationale is speculative and the safety direction is ambiguous at best.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

US Market Information

No license/authorization records are available for pegfilgrastim in this evidence pack (market status: 未上市, total licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

(Note: safety.key_warnings, safety.contraindications, and safety.ddi are all marked as Data Gap or not found in this evidence pack — this is a Blocking data gap per DG001, meaning safety evaluation (S1 stage) cannot proceed until TFDA label warnings/contraindications are obtained.)

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is L5 evidence level — a model-only inference with zero supporting clinical trials or literature, and the proposed mechanistic link runs against the known pro-angiogenic risk profile of G-CSF agents in a retinal neovascular disease context. There is currently no basis to advance this candidate beyond hypothesis generation.

To proceed, the following is needed:

TFDA (or equivalent) label warnings and contraindications (blocking gap, DG001) before any safety screening can begin
Documented mechanism of action (MOA) data from DrugBank or primary literature (DG002)
Preclinical or observational evidence directly evaluating G-CSF/pegfilgrastim in diabetic retinopathy, specifically addressing the theoretical risk of exacerbating pathological neovascularization
Confirmation of original approved indication(s), which are currently missing from the regulatory record
Given the potential safety signal (pro-angiogenic mechanism vs. retinal neovascular disease), any future evaluation should explicitly include an ophthalmology/retinal safety risk assessment before considering further development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.